C4X Discovery Holdings PLC Exercise of Options and Issue of Equity (6694E)

TIDMC4XD

RNS Number : 6694E

C4X Discovery Holdings PLC

19 October 2018

C4X Discovery Holdings plc

("C4XD" or the "Company")

Exercise of Options

Issue of Equity

19 October 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces it has today issued 26,875 new ordinary shares of 1p each in the Company ("New Ordinary Shares") following the exercise of options by a former employee of the Company .

Application has been made for the New Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 8.00 a.m. on 26 October 2018.

The New Ordinary Shares rank pari passu with the existing shares of the Company. Following the issue of the New Ordinary Shares, the Company's issued share capital now consists of 57,792,636 ordinary shares. Accordingly, the figure of 57,792,636 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer 07801 865 803

Panmure Gordon (UK) Limited (NOMAD) 020 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Consilium Strategic Communications 020 3709 5700

Mary-Jane Elliott, Matthew Neal, Chris Gardner

About C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards pre-clinical licensing discussions. In selecting and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294 million.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com

--ENDS----

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

IOEFKCDBPBDDCKD

(END) Dow Jones Newswires

October 19, 2018 11:33 ET (15:33 GMT)